Condition: Gastrointestinal Neuroendocrine Pancreatic Tumor · Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
The purpose of this study is to compare the effectiveness, safety, pharmacokinetics (PK) of SYHX2008 vs Octreotide Microspheres (Sandostatin LAR@) in patients with advanced, well-differentiated GEP-NET.
This description comes directly from the study's public registry record.
Clinical Trials Information Group officer · 86-0311-69085587 · ctr-contact@cspc.cn
Jianming Xu, M.D · 010-66947176 · Jianmingxu2014@163.com
Always discuss trial participation with your own doctor first.
| Chinese PLA General Hosptial | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06505395